First Time Loading...

Eyenovia Inc
NASDAQ:EYEN

Watchlist Manager
Eyenovia Inc Logo
Eyenovia Inc
NASDAQ:EYEN
Watchlist
Price: 0.986 USD -0.04% Market Closed
Updated: Mar 29, 2024

Intrinsic Value

EYEN's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

Eyenovia, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of ophthalmology products. [ Read More ]

The intrinsic value of one EYEN stock under the Base Case scenario is 4.062 USD. Compared to the current market price of 0.986 USD, Eyenovia Inc is Undervalued by 76%.

Key Points:
EYEN Intrinsic Value
Base Case
4.062 USD
Undervaluation 76%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Eyenovia Inc

Backtest EYEN Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling EYEN stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Eyenovia Accelerates Commercial Strategy in Q4 2023
2023-Q4 Earnings Call

Eyenovia Accelerates Commercial Strategy in Q4 2023

In the fourth quarter of 2023, Eyenovia advanced its commercial strategy with two FDA-approved products and two more in Phase III. The company highlighted its revenue growth strategies, including expanding its sales force and signing co-promotion agreements with NovaBay and Vision Source. They are also exploring a new opportunity in dry eye treatment, a market valued at over $3.6 billion. Eyenovia reported a net loss of $8 million for Q4 and $27.3 million for the year. They've generated $16 million in license fees to date and stand to earn an additional $25 million in milestones. With a focus on its Optejet technology, the company is positioned for growth, particularly as it makes strides in addressing pediatric myopia with MicroPine and expands its manufacturing capabilities.

Financials

Balance Sheet Decomposition
Eyenovia Inc

Current Assets 20.7m
Cash & Short-Term Investments 14.8m
Receivables 624.5k
Other Current Assets 5.2m
Non-Current Assets 8.1m
PP&E 5m
Intangibles 2.1m
Other Non-Current Assets 908.6k
Current Liabilities 9.5m
Accounts Payable 1.8m
Accrued Liabilities 2.4m
Other Current Liabilities 5.4m
Non-Current Liabilities 10.2m
Long-Term Debt 9m
Other Non-Current Liabilities 1.3m
Efficiency

Earnings Waterfall
Eyenovia Inc

Revenue
3.8k USD
Operating Expenses
-25.4m USD
Operating Income
-25.4m USD
Other Expenses
-1.9m USD
Net Income
-27.3m USD

Free Cash Flow Analysis
Eyenovia Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

EYEN Profitability Score
Profitability Due Diligence

Eyenovia Inc's profitability score is 18/100. The higher the profitability score, the more profitable the company is.

18/100
Profitability
Score

Eyenovia Inc's profitability score is 18/100. The higher the profitability score, the more profitable the company is.

EYEN Solvency Score
Solvency Due Diligence

Eyenovia Inc's solvency score is 35/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Negative Net Debt
Long-Term Solvency
Low D/E
35/100
Solvency
Score

Eyenovia Inc's solvency score is 35/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

EYEN Price Targets Summary
Eyenovia Inc

Wall Street analysts forecast EYEN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for EYEN is 12.58 USD with a low forecast of 10.1 USD and a high forecast of 15.75 USD.

Lowest
Price Target
10.1 USD
924% Upside
Average
Price Target
12.58 USD
1 176% Upside
Highest
Price Target
15.75 USD
1 497% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

EYEN Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

EYEN Price
Eyenovia Inc

1M 1M
-54%
6M 6M
-41%
1Y 1Y
-69%
3Y 3Y
-81%
5Y 5Y
-84%
10Y 10Y
-90%
Annual Price Range
0.986
52w Low
0.986
52w High
5.75
Price Metrics
Average Annual Return -18.94%
Standard Deviation of Annual Returns 44.71%
Max Drawdown -87%
Shares Statistics
Market Capitalization 44.9m USD
Shares Outstanding 44 122 200
Percentage of Shares Shorted 7.62%

EYEN Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Eyenovia Inc Logo
Eyenovia Inc

Country

United States of America

Industry

Pharmaceuticals

Market Cap

44.9m USD

Dividend Yield

0%

Description

Eyenovia, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of ophthalmology products. The company is headquartered in New York City, New York and currently employs 43 full-time employees. The company went IPO on 2018-01-25. The firm is developing a pipeline of therapeutics based on its microdose array print (MAP) platform technology. Its pipeline is focused on the late-stage development of therapeutic indications for pediatric patients with progressive myopia in the United States and patients with age-related near vision impairment, or presbyopia indications. The firm is also developing the microdose fixed combination ophthalmic pharmaceutical for mydriasis. The firm's product candidates include MicroLine (for presbyopia), MicroPine (for progressive myopia) and Mydcombi (for mydriasis). MicroLine is its microdosed version of pilocarpine, an ophthalmic medication that can dose-dependently induce miosis, or a contraction of the pupil. MicroPine is a topical treatment for progressive myopia, a back-of-the-eye disease. Mydcombi is a fixed combination micro-formulation product candidate for mydriasis (eye dilation).

Contact

NEW YORK
New York City
295 Madison Ave Ste 2400
+18137669539.0
https://eyenovia.com/

IPO

2018-01-25

Employees

43

Officers

Co-Founder & Executive Chairman
Dr. Tsontcho Ianchulev M.D., M.P.H., MPH
CEO & Director
Mr. Michael M. Rowe
CFO & Secretary
Mr. John P. Gandolfo CPA
COO & Corporate VP
Mr. Bren Kern
Investor Contact
Alexander Lobo

See Also

Discover More
What is the Intrinsic Value of one EYEN stock?

The intrinsic value of one EYEN stock under the Base Case scenario is 4.062 USD.

Is EYEN stock undervalued or overvalued?

Compared to the current market price of 0.986 USD, Eyenovia Inc is Undervalued by 76%.